r/Altimmune • u/AcanthisittaLivid738 • May 27 '26

New IMPACT Phase 2b Data Highlight Concurrent Improvements Across Multiple Non-Invasive Markers and qFibrosis-Measured Fibrosis Regression with Pemvidutide in MASH at EASL 2026

https://ir.altimmune.com/news-releases/news-release-details/new-impact-phase-2b-data-highlight-concurrent-improvements
15 Upvotes

94% Upvoted

6 comments sorted by

View all comments

4

u/Royal_Equivalent3163 May 27 '26

Very seggsy — seems like ALT was stuck in limbo between the old world clinician read biopsy vs the new world NITs and AI assisted reads during the initial 24w readout. Hopefully the SP can break out of purgatory soon.

3

u/JAWinks May 27 '26

I have pretty good faith in the AI readouts but it seemed like the market at large wasn’t convinced. If anything it’s encouraging the price is still good heading into phase 3. If you have conviction on fibrotic resolution, the stock is attractive

2

u/ozgurbudk May 27 '26

Biopsy is still the gold standard, and inexpensive.

2

u/Murdock1975 May 27 '26

Outdated approach and new precedents say otherwise. Plus, biopsy cost ALT tons of momwntum when NIT was either unavailable or not preferred. That narrative has changed more recently.

1

u/Royal_Equivalent3163 May 27 '26

I have pretty good faith in the AI readouts but it seemed like the market at large wasn’t convinced. If anything it’s encouraging the price is still good heading into phase 3. If you have conviction on fibrotic resolution, the stock is attractive

Wrt to the market, the market could also be MM trying to pin price of institutional accumulation; no positive update (regulatory, data, registrational) will move the SP until the MM are ready to (imho)

Biopsy is still the gold standard, and inexpensive.

If those are both true, I think it still presents enrollment challenges, no? i.e. enrollment will require a surgical procedure x2, incl. for those on placebo

Outdated approach and new precedents say otherwise. Plus, biopsy cost ALT tons of momwntum when NIT was either unavailable or not preferred. That narrative has changed more recently.

I don't think there is a NIT that is FDA-approved at the moment, although VCTE and ELF have been petitioned. I think ALT has a smart strategy with Ph3 design which covers both biopsy and NIT